Component
R59022, pharmacological DGK inhibitor
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
DGK inhibitor R59022 attenuated CLA-induced calcium accumulation and reductions in glucose/fatty-acid uptake.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Primary human adipocytes, R59022 pretreatment.
- limitations
- The inhibitor does not establish DGK-eta as the calcium-controlling isoform.
- nutrient_topic
- CLA collection; isomer, preparation, species, exposure and manipulation remain explicit. · Conjugated linoleic acid / CLA isomer family
- plain_language
- Pharmacological results connected lipid signaling and calcium.
- primary_references
- Diacylglycerol kinase inhibitor R59022 attenuates conjugated linoleic acid-mediated inflammation in human adipocytes. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23264678/ · DOI 10.1194/jlr.M031211
Conjugated linoleic acid: isomers, signaling, nutrient interactions and discovery (2026-09-19) · lines 198–204
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Primary human adipocytes, R59022 pretreatment. · source_derived_draft · unverified_draft
## cla-dgk-inhibitor Pharmacological results connected lipid signaling and calcium. DGK inhibitor R59022 attenuated CLA-induced calcium accumulation and reductions in glucose/fatty-acid uptake. Model: Primary human adipocytes, R59022 pretreatment. Limitations: The inhibitor does not establish DGK-eta as the calcium-controlling isoform. Evidence access: Primary abstract Diacylglycerol kinase inhibitor R59022 attenuates conjugated linoleic acid-mediated inflammation in human adipocytes. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23264678/ · DOI 10.1194/jlr.M031211
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.